The Potassium Voltage Gated Channel Subfamily KQT Member 4 pipeline drugs market research report outlays comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Potassium Voltage Gated Channel Subfamily KQT Member 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ear Nose Throat Disorders, and Central Nervous System which include the indications Hearing Disorders, Acute Sensorineural Hearing Loss, Amyotrophic Lateral Sclerosis, and Diabetic Neuropathic Pain. It also reviews key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Potassium Voltage Gated Channel Subfamily KQT Member 4 pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 1, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Potassium Voltage Gated Channel Subfamily KQT Member 4 overview
Potassium voltage-gated channel subfamily KQT member 4, also known as voltage-gated potassium channel subunit Kv7.4, is a protein that in humans is encoded by a gene KCNQ4. The protein encoded by this gene forms a potassium channel that is thought to play a critical role in the regulation of neuronal excitability, particularly in sensory cells of the cochlea. The current generated by this channel is inhibited by M1 muscarinic acetylcholine receptors. The encoded protein can form a homomultimeric potassium channel or possibly a heteromultimeric channel in association with the protein encoded by the KCNQ3 gene. Defects in this gene are a cause of nonsyndromic sensorineural deafness type 2 (DFNA2), an autosomal dominant form of progressive hearing loss.
For a complete picture of Potassium Voltage Gated Channel Subfamily KQT Member 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
